W e present a case of a 43-year-old Caucasian female with acute myeloid leukaemia (AML), who developed Epstein-Barr virus (EBV) positive post-transplant lymphoproliferative disorder (PTLD) of duodenum, with plasma cell differentiation after second haematopoietic stem cell transplantation. The patient was given rituximab and CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone); however, these were only temporarily effective, and the patient passed away 36 days after PTLD was diagnosed. PTLD with plasma cell differentiation is a rare type of PTLD, and there are no strict treatment guidelines.
Post-transplant lymphoproliferative disorder (PTLD) is a severe complication of haematopoietic stem cell transplantation (HSCT). Most of the PTLDs originate from B-cells. Overall, 60-80% of PTLDs are associated with Epstein-Barr virus (EBV); this can vary depending on PTLD type and time of onset after HSCT. 1, 2 The majority of the general population is infected by EBV during their life, but an immunocompetent host mounts a swift immune response that controls proliferation of EBV infected B-cells. EBV then resides only in resting memory B-cells in latent form. 3 The balance between latently infected B-cells and immune surveillance is disrupted after a patient receives
HSCT. An increase in the number of infected B-cells (almost always of donor origin) may develop into PTLD. [4] [5] [6] PTLDs are divided into three stages of evolution: early lesions, polymorphic PTLDs and monomorphic PTLDs. Monomorphic PTLDs are mostly derived from B-cells, but can also be of T-cell origin, and resemble aggressive non-Hodgkin lymphomas. 5 PTLD resembling diffuse large B-cell lymphoma (DLBCL) is the most common. 7 Rituximab, an anti CD20 monoclonal antibody, can be used effectively to treat them. 8, 9 Other types of PTLD are rare and only 4% of them show plasma cell differentiation. 7, 10 We would therefore like to present our patient with PTLD of duodenum with plasma cell differentiation.
Case report
A 43-year-old Caucasian female was diagnosed with MLL/PTD-and FLT3/ITD-positive acute myeloid leukaemia (AML) in June 2013. She was given "3+7" induction chemotherapy regimen (cytarabine 100 mg/m 2 for 7 days and daunorubicin 90 mg/m 2 for 3 days) followed by consolidation chemotherapy high-dose cytarabine (HiDAC) in July 2013. She achieved complete remission (CR) with negative minimal residual disease (polymerase chain reaction [PCR] for MLL/PTD gene). Five days later she developed severe sepsis with renal impairment.
Antibiotic therapy was escalated (linezolid) and renal replacement therapy was started. On day 87 the PTLD rapidly progressed: 29% monoclonal plasma cells in her blood via FACS, 4.35x10 6 EBV copies/ml and further elevation of paraproteinaemia (9.2 g/l) was present.
The failing rituximab monotherapy was replaced by the second-line treatment (rituximab 375 mg/m 2 for 1 day, cyclophosphamide 600 mg/m 2 for 1 day and methylprednisolone 2 mg/kg for 5 days). 11 Her condition temporarily improved with disappearance of sepsis signs so antibiotic therapy was deescalated. On day 92 the patient was again septic with severe diarrhoea. Broad spectrum antibiotics were again administered (meropenem, linezolid, amikacin). The EBV blood levels were again rising rapidly ( Figure 1) . CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) was given as the third line of therapy on day 101. Despite all the treatment, the patient went into septic shock and died on 19 January, day 102.
Discussion
PTLD is a heterogeneous group of diseases and there are no strict guidelines for therapeutic approach. One of the options is reduction of immune suppression (RI) but it only occasionally results in CR, and is mostly effective for early lesions. 7 Rituximab can be used as the first line of therapy for most of the newly diagnosed polymorphic and monomorphic PTLDs and plays a prominent role in treatment. Several studies strongly suggest that early introduction of rituximab-based therapy significantly improves overall survival. 9 Evens et al. performed a multicentre analysis of 80 patients with PTLD after solid organ transplant. A 3-year progressionfree survival and overall survival for patients who received firstline rituximab-based therapy were 70% and 73%, compared with 21% and 33% among patients who did not receive it as a component of initial therapy. 
The trend of EBV copies in peripheral blood with LDH (A), bilirubin (B) and monoclonal plasmatic cells (C). EBV = Epstein-Barr virus; FACS = fluorescence-activated cell sorting; LDH = lactate dehydrogenase.
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1.00E+08 Out of the six patients who received a RI as a first line of therapy two responded, and four patients showed progressive disease. The three patients with disseminated and progressive disease after RI, received systemic chemotherapy analogous to therapy of multiple myeloma. All three responded to treatment including one CR after chemotherapy consisting of bortezomib, doxorubicin and dexamethasone. One patient eventually died from disease progression. None of the patients received rituximab, as staining for CD20 was negative in all cases. 7 Our patient's plasmatic cells were CD138 positive, CD20 negative, CD56 negative and showed lambda light chain restriction (Figure 2) . The patient presented with LDH elevation and elevated EBV levels in blood. Elevated bilirubin levels correlated with activity of PTLD (Figure 1) . Despite being CD20 negative the rituximab therapy was capable of reducing an amount of EBV blood levels and number of monoclonal plasma cells in blood, if only temporarily ( Figure 1) . As a second line of therapy the patient was given combination of rituximab, cyclophosphamide and methylprednisolone, a regimen used by Gross for patients who failed in first-line therapy for PTLD after solid-organ transplant. Overall, a response rate of 83% and CR of 75% was achieved in 36 patients. 11 Our patient's EBV copies in blood temporarily lowered. But even this regimen helped only for a short period of time. 
